Internal Medicine, Rheumatology · Ruston, LA
NPI
1750575890
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1200 S Farmerville St
Ruston, LA, 71270
Phone (318) 255-3690
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.6M
194,922 services
Medicare patients, 2024
765
Average age 73
Drug cost, 2024
$3.9M
5,799 prescriptions
Company payments, 2025
$752
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rochelle Robicheaux Metoyer was code J3262 (injection, tocilizumab, 1 mg), 55,600 times for 15 patients. In total Rochelle Robicheaux Metoyer billed 194,922 services in 58 codes, and Medicare paid $3.6M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-06-13.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 55,600 | 15 | $4.71 | $262K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 46,725 | 67 | $32.96 | $1.5M |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 40,550 | 53 | $8.86 | $359K |
| J9312 Injection, rituximab, 10 mg | Office | 7,940 | 25 | $61.29 | $487K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 6,924 | 28 | $24.96 | $173K |
| J0897 Injection, denosumab, 1 mg | Office | 5,521 | 86 | $20.00 | $110K |
| Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 4,070 | 18 | $23.35 | $95K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 2,902 | 34 | $0.22 | $649 |
| 99215 Office E&M - Established | Office | 1,432 | 533 | $121.54 | $174K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,320 | 21 | $0.10 | $134 |
| 96365 Intravenous Infusion, Hydration | Office | 724 | 135 | $41.20 | $30K |
| 96413 Chemotherapy Administration | Office | 653 | 127 | $80.71 | $53K |
| 96415 Chemotherapy Administration | Office | 589 | 70 | $18.02 | $11K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 370 | 74 | $4.94 | $1,828 |
| 99214 Office E&M - Established | Office | 343 | 220 | $84.88 | $29K |
By year: 2022 $2.6M for 110,801 services; 2023 $3.1M for 146,940 services; 2024 $3.6M for 194,922 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rochelle Robicheaux Metoyer prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 687 prescriptions and refills. In total Rochelle Robicheaux Metoyer wrote 5,799 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 687 | 1,753 | 222 | $43K |
| Prednisone Generic | 617 | 1,097 | 229 | $3,824 |
| Methotrexate Methotrexate Sodium | 554 | 1,044 | 153 | $15K |
| Duloxetine Hcl Generic | 488 | 1,223 | 124 | $12K |
| Leflunomide Generic | 454 | 955 | 147 | $35K |
| Gabapentin Generic | 310 | 743 | 105 | $6,065 |
| Sulfasalazine Generic | 298 | 654 | 83 | $8,952 |
| Tizanidine Hcl Generic | 262 | 699 | 101 | $4,402 |
| Celecoxib Generic | 164 | 385 | 59 | $3,703 |
| Humira(Cf) Pen Adalimumab | 95 | 99 | 14 | $1.0M |
| Alendronate Sodium Generic | 95 | 219 | 36 | $1,043 |
| Meloxicam Generic | 90 | 225 | 40 | $605 |
| Mycophenolate Mofetil Generic | 87 | 186 | 24 | $14K |
| Tramadol Hcl Generic | 83 | 85 | 33 | $484 |
| Pregabalin Generic | 79 | 91 | 15 | $2,047 |
Brand drugs: - claims; generic drugs: 4,884 claims; opioid claims: 157.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rochelle Robicheaux Metoyer $752 ($752 in general payments such as food, travel and fees) from 9 companies. The largest payer was Abbvie Inc. with $208.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.